Topical Infliximab in Eyes With Penetrating Keratoplasty
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 80 years; * First corneal transplant surgery; * Capable of providing informed consent; * Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient. Exclusion Criteria: * Active ocular infection; * Past corneal transplant (any technique); * Advanced glaucoma or macular disease; * Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B); * Malignancy diagnosed in the past 5 years (any kind); * Demyelinating disease; * History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV); * Pregnancy or breastfeeding; * Allergy to infliximab or to a compound of its topical formulation; * Significant anomaly of complete blood count or hepatic enzymes; * Current or anterior use of anti-TNF-α medication or other anti-inflammatory bio